Trial · NCT07891819
Acupuncture Versus Conventional Treatment for Chronic Pain in Patients With Chronic Kidney Disease
NCT07891819, Not applicable, Completed, Federal University of São Paulo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acupuncture Versus Conventional Treatment for Chronic Pain in Patients With Chronic Kidney Disease. Trials, record NCT07891819. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891819
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acupuncture Versus Conventional Treatment for Chronic Pain in Patients With Chronic Kidney Disease
- NCT number
- NCT07891819
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 110 participants, actual
- Lead sponsor
- Federal University of São Paulo
- Conditions
- Chronic Pain, Neuralgia, Renal Insufficiency,Chronic
- Interventions
- Acupuncture, Optimized conventional pharmacological treatment
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in pain intensity from baseline to the final study visit | Baseline and 5 months | Change in pain intensity from baseline to 5 months, measured using the 0-to-10 Visual Analog Scale (VAS) for pain, where 0 indicates no pain and 10 the worst imaginable pain. Higher scores indicate worse pain; a negative change indicates improvement. |
| Secondary | Proportion of participants achieving a reduction of at least 2 points in pain intensity | Baseline and 5 months | Proportion of participants with a reduction of at least 2 points in pain intensity on the 0-to-10 Visual Analog Scale (VAS) for pain, where 0 indicates no pain and 10 the worst imaginable pain, from baseline to 5 months. |
| Secondary | Change in limitation of daily activities | Baseline to 5 months | Change from baseline to the final study visit in pain-related limitation of daily activities, assessed with the Daily Activity Assessment Scale (Escala de Avaliação de Atividade Diária). This categorical scale has five possible scores: 0 (no pain), 3 (pain present, with periods when it is forgotten), 6 (pain is not forgotten but does not prevent activities of daily living), 8 (pain is not forgotten and interferes with all activities of daily living except eating and personal hygiene), and 10 (pain persists even at rest and cannot be ignored; rest is imperative). Scores range from 0 to 10, with higher scores indicating a worse outcome. A negative change indicates improvement. |
| Secondary | Adverse events | From baseline through 5 months | Frequency and characteristics of adverse events, including serious adverse events, events considered related to the intervention, and events leading to interruption of treatment. |
| Secondary | Change in SF-36 scores | Baseline and 5 months | Descriptive assessment of change in quality of life from baseline to 5 months, measured with the 36-Item Short Form Health Survey (SF-36), Brazilian Portuguese validated version. Owing to logistical constraints, the SF-36 was administered only to a subsample of participants (n = 35), at baseline and monthly through 5 months. Results are reported for the eight SF-36 domains (physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), each scored from 0 to 100, with higher scores indicating better health status (for the bodily pain domain, higher scores indicate less pain). A positive change indicates improvement. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891819
GET https://conductscience.org/api/trials/v1/NCT07891819/registered